Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies
Christian Chabannon, Jurgen Kuball, Attilio Bondanza, Francesco Dazzi, Paolo Pedrazzoli, Antoine Toubert, Annalisa Ruggeri, Katharina Fleischhauer, Chiara Bonini
Index: 10.1126/scitranslmed.aap9630
Full Text: HTML
Abstract
Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation.
Latest Articles:
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
2018-04-11
[10.1126/scitranslmed.aao3003]
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
2018-04-11
[10.1126/scitranslmed.aan3311]
Spooked neutrophils unmask sepsis
2018-04-11
[10.1126/scitranslmed.aat3891]
Adult neurogenesis in humans: Dogma overturned, again and again?
2018-04-11
[10.1126/scitranslmed.aat3893]
2018-04-11
[10.1126/scitranslmed.aan8292]